tbuckley/cabot-search huggingface dataset:
Surgeon gives patient a vasectomy by mistake
Authors: C. Dyer
Journal: BMJ (2014)

A surgeon in Liverpool has been suspended from operating pending an investigation, after a man who was booked for a minor urological operation was given a vasectomy instead.

Surgeons performed a reversal, but it is not yet certain whether the procedure, which has a success rate of only around 55%, has been effective.

“Never events”—identified by NHS England as “serious, largely preventable patient safety incidents …
Deposition of Radioaerosol Throughout the Major Airways in Tracheobronchitis
Authors: IZZIE BOXEN, ZONG MEI ZHANG
Journal: Clinical Nuclear Medicine (1990)

From the University of Toronto, Department of Nuclear Medicine, Princess Margaret Hospital, Toronto, Ontario, Canada Received for publication November 16, 1989; revision accepted January 22, 1990. Reprint requests: I. Boxen, M.D., Department of Nuclear Medicine, Princess Margaret Hospital, 500 Sherbourne Street, Toronto, Ontario, Canada M4X 1K9.
Abstract 3044: A new paradigm for ABCB6: Role in growth and proliferation
Authors: Kishore K. Polireddy, Hemant Chavan, Partha C. Krishnamurthy
Journal: Cancer Research (2012)

Abstract ABCB6 is a mitochondrial ATP binding cassette (ABC) transporter whose expression is upregulated in a broad spectrum of primary human cancers, including hepatocellular carcinoma (HCC). We recently demonstrated that in hepatoma cells ABCB6 expression promotes growth and proliferation. In contrast, loss of ABCB6 expression in these hepatomas precipitates a delay in progression through G2/M phase of the cell cycle. As histone H3 is specifically phopshorylated during mitosis, we took advantage of the H3 phosphorylated antibody to separate G2 phase of the cell cycle from the M-phase. Using this approach, we demonstrate that loss of ABCB6 expression leads to a delay in M phase and not the G2 phase of the cell cycle. However, it is not clear how a mitochondrial transporter, originally characterized as a transporter of porphyrins, regulates cell growth. We have proposed two broad hypotheses to evaluate the mechanism by which ABCB6 regulates growth and proliferation; 1) ABCB6 functionally interacts with one or more of the cell cycle regulatory components, thus precipitating M phase delay; 2) ABCB6s’ location and function as a mitochondrial membrane transporter alters mitochondrial dynamics leading to some level of control over cellular proliferation. To test our proposed first hypothesis we have begun a systematic evaluation of the expression and function of cell cycle regulatory components in response to ABCB6 expression. Results from these studies demonstrate that ABCB6 expression alters the expression of cyclin-dependent kinase inhibitors p16, p21 and p27. In addition, yeast two-hybrid screening and protein interaction studies reveal that ABCB6 interacts with p21 and a novel tumor susceptibility protein-101 (TSG-101). TSG 101 co-localizes with microtubule organizing centers and mitotic spindles during mitosis and its deficiency is associated with abnormalities in microtubules, genetic instability and carcinogenesis. In this report, we provide evidence of the physical and functional interactions between ABCB6 and cell cycle regulatory components and explore the significance of these interactions to growth and proliferation. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3044. doi:1538-7445.AM2012-3044
&lt;emph type="ital"&gt;Study for Phidias in the&lt;/emph&gt; Apotheosis of Homer
Authors: Thomas B. Cole
Journal: JAMA (2010)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
High-Altitude Pulmonary Edema Is Initially Caused by an Increase in Capillary Pressure
Authors: Marco Maggiorini, Christian Mélot, Sebastien Pierre, Fredi Pfeiffer, Ilona Greve, Claudio Sartori, Mattia Lepori, Markus Hauser, Urs Scherrer, Robert Naeije
Journal: Circulation (2001)

Background —High-altitude pulmonary edema (HAPE) is characterized by severe pulmonary hypertension and bronchoalveolar lavage fluid changes indicative of inflammation. It is not known, however, whether the primary event is an increase in pressure or an increase in permeability of the pulmonary capillaries. Methods and Results —We studied pulmonary hemodynamics, including capillary pressure determined by the occlusion method, and capillary permeability evaluated by the pulmonary transvascular escape of 67 Ga-labeled transferrin, in 16 subjects with a previous HAPE and in 14 control subjects, first at low altitude (490 m) and then within the first 48 hours of ascent to a high-altitude laboratory (4559 m). The HAPE-susceptible subjects, compared with the control subjects, had an enhanced pulmonary vasoreactivity to inspiratory hypoxia at low altitude and higher mean pulmonary artery pressures (37±2 versus 26±1 mm Hg, P &lt;0.001) and pulmonary capillary pressures (19±1 versus 13±1 mm Hg, P &lt;0.001) at high altitude. Nine of the susceptible subjects developed HAPE. All of them had a pulmonary capillary pressure &gt;19 mm Hg (range 20 to 26 mm Hg), whereas all 7 susceptible subjects without HAPE had a pulmonary capillary pressure &lt;19 mm Hg (range 14 to 18 mm Hg). The pulmonary transcapillary escape of radiolabeled transferrin increased slightly from low to high altitude in the HAPE-susceptible subjects but remained within the limits of normal and did not differ significantly from the control subjects. Conclusions —HAPE is initially caused by an increase in pulmonary capillary pressure.
GPs get a new contract "to transform their lives"
Authors: Z. Kmietowicz
Journal: BMJ (2002)

GPs are being offered a brand new contract that promises to transform their working lives and end the disillusionment that has pervaded the profession for the past decade, hampering recruitment and driving many doctors out of general practice.

For the first time—if the proposals are accepted—GPs throughout the United Kingdom will be contracted to their practice or primary care trust rather than to the NHS and will have the option of drawing a salary rather than operating as independent contractors. They will also stop having 24 hour responsibility for their patients …
CERTAIN CONDITIONS OF THE TONSILS WHICH LIMIT THE USEFULNESS OF THE TONSILLOTOME.
Authors: ARTHUR AMES BLISS
Journal: JAMA (1898)

Dr. Roe-The apparatus devised by Dr. Cobb for the treat- ment of fracture of the nasal bones is an ingenious one, but he has evidently made it without previous knowledge of a sim- ilar instrument that was devised several years ago by Adams of London, called Adams' nasal truss, which is figured in Wat- son on " Diseases of the Nose."Longitudinal fractures of the bones of the nose, as a rule, require little or no retentive appa- ratus, for the bones almost always remain in place after the fracture is reduced ; but transverse fractures of the nasal bones will not remain in place and therefore require retentive
Biochemical determinants of clearance of tissue-type plasminogen activator from the circulation.
Authors: C L Lucore, E T Fry, D A Nachowiak, B E Sobel
Journal: Circulation (1988)

Biochemical modification of tissue-type plasminogen activator (t-PA) designed to alter pharmacokinetics and pharmacodynamics offers promise for development of pharmaceuticals particularly suitable for treatment of specific disorders and for induction of coronary thrombolysis by intramuscular as well as intravenous administration. Accordingly, to identify biochemical determinants of clearance of t-PA from the circulation, we injected rabbits intravenously with three different preparations of t-PA synthesized from the same human gene and expressed in Chinese hamster ovary cells cultured under disparate conditions. Influences of glycosylation on clearance were defined by experiments with enzymatically treated t-PA in which clearance was assessed with concomitant administration of selected neoglycoproteins that compete with t-PA for specific glycoprotein receptors. The role of an intact active catalytic site, as reflected by differences in clearance with and without prior treatment of t-PA with the protease inhibitor PPACK, was defined also. Results indicate that clearance is altered by inhibition of the active site and that the nature and extent of glycosylation--not evident simply by analysis of peptide structure--influence clearance as well. These findings suggest that mannose/N-acetylglucosamine-specific glycoprotein receptors expressed on hepatic reticuloendothelial cells participate in clearance of t-PA from the circulation but that galactose-specific glycoprotein receptors probably do not. The observations may explain differences in clearance seen with different preparations of t-PA that have been seen in clinical pilot studies and may identify biochemical determinants of clearance amenable to modification for development of agents with potentially desirable, specific biological properties.
Functional switching of macrophage responses to tumor necrosis factor-alpha (TNF alpha) by interferons. Implications for the pleiotropic activities of TNF alpha.
Authors: F R Lake, P W Noble, P M Henson, D W Riches
Journal: Journal of Clinical Investigation (1994)

Recent work conducted in our laboratory has been directed towards understanding the role of TNF alpha in stimulating the synthesis of two macrophage gene products, namely IGF-1, a growth factor implicated in wound repair and fibrosis, and complement component factor B (Bf), an alternative pathway complement component. The expression of these proteins is induced by hyaluronic acid and poly (I:C), respectively, although TNF alpha plays a requisite role in the expression of both proteins. The objective of this study was to determine the mechanism governing the dichotomy in the expression of IGF-1 and Bf by TNF alpha. First, we questioned if the diversity in IGF-1 and Bf synthesis was regulated at the level of TNF receptor usage. Second, based on earlier findings that IFNs contribute to the initiation of Bf expression, we determined if IFNs modulate the response of macrophages to TNF alpha. Our data show that differences in TNF receptor usage cannot fully explain the dichotomy in the expression of IGF-1 and Bf. However, prior exposure to IFN-beta or IFN-gamma was found to be a dominant factor controlling the expression of these proteins, suppressing IGF-1, and enhancing Bf. These findings indicate that IFNs mediate a functional "switch" in the response of macrophages to TNF alpha and suggest that the pattern of cytokine expression by diverse macrophage stimuli is an important determinant of the eventual responses of macrophages to TNF alpha.
Hepatic disease in patients with the acquired immune deficiency syndrome (AIDS)
Authors: David J. Schneiderman, David M. Arenson, John P. Cello, William Margaretten, Thomas E. Weber
Journal: Hepatology (1987)

The spectrum of liver disease in patients with acquired immune deficiency syndrome (AIDS) and the clinical impact of diagnostic percutaneous liver biopsy in this population were evaluated by a retrospective review of hepatic histology, clinical features and laboratory data in 85 patients (26 biopsies, 59 autopsies). Only 1 (3.8%) biopsy and 9 (15%) postmortem livers were histologically normal. Macrosteatosis and nonspecific portal inflammation were the most common histologic abnormalities. Intrahepatic AIDS-specific opportunistic infections or malignancies were detected in 42% of both biopsy and autopsy groups, with Mycobacterium avium-intracellulare the most frequent pathogen seen. Kaposi's sarcoma, although not detected on biopsy, was the most common postmortem AIDS-related hepatic finding. Intrahepatic lymphoma, cytomegalovirus hepatitis and hepatic mycoses were less frequently observed. In general, hepatic involvement represented part of a previously diagnosed, widely disseminated disease process, and liver biopsy led to new AIDS-specific diagnoses in only two patients. We conclude that while liver biopsy is a useful diagnostic tool in selected patients with AIDS, the information provided by biopsy rarely influences therapy or leads to improved survival.
Doxorubicin-Induced Cardiac Toxicity
Authors: James H. Doroshow
Journal: New England Journal of Medicine (1991)

Doxorubicin (Adriamycin) and the related anthracycline antibiotic daunorubicin play a central part in cancer therapy because of their efficacy in the treatment of hematologic cancers (both acute leukemias and lymphomas), as well as carcinomas of the breast, lung, and thyroid and bone and soft-tissue sarcomas.1 Furthermore, these drugs are widely used in both adults and children in treatment regimens aimed at the cure of neoplasms as well as at palliation. The discovery more than 20 years ago that therapy with anthracyclines could produce irreversible and possibly life-threatening cardiac injury has led to limitations on the use of these drugs in . . .
890-4 Identification and characterization during sinus rhythm of a mitral isthmus in patients with inferior myocardial infarction and monomorphic ventricular tachycardia
Authors: Angel Arenal, Mercedes Ortiz, Esteban Gonzalez Torrecilla, Felipe Atienza, Javier Jimenez Candil, Alberto Puchol, Juan Jose Gomez de Diego, Ana Sanchez Hernandez
Journal: Journal of the American College of Cardiology (2004)
Menopausal Hormone Replacement Therapy and Risk of Ovarian Cancer
Authors: James V. Lacey, Pamela J. Mink, Jay H. Lubin, Mark E. Sherman, Rebecca Troisi, Patricia Hartge, Arthur Schatzkin, Catherine Schairer
Journal: JAMA (2002)

ContextThe association between menopausal hormone replacement therapy and ovarian cancer is unclear.ObjectiveTo determine whether hormone replacement therapy using estrogen only, estrogen-progestin only, or both estrogen only and estrogen-progestin increases ovarian cancer risk.DesignA 1979-1998 cohort study of former participants in the Breast Cancer Detection Demonstration Project, a nationwide breast cancer screening program.SettingTwenty-nine US clinical centers.ParticipantsA total of 44 241 postmenopausal women (mean age at start of follow-up, 56.6 years).Main Outcome MeasureIncident ovarian cancer.ResultsWe identified 329 women who developed ovarian cancer during follow-up. In time-dependent analyses adjusted for age, menopause type, and oral contraceptive use, ever use of estrogen only was significantly associated with ovarian cancer (rate ratio [RR], 1.6; 95% confidence interval [CI], 1.2-2.0). Increasing duration of estrogen-only use was significantly associated with ovarian cancer: RRs for 10 to 19 years and 20 or more years were 1.8 (95% CI, 1.1-3.0) and 3.2 (95% CI, 1.7-5.7), respectively (P value for trend <.001), and we observed a 7% (95% CI, 2%-13%) increase in RR per year of use. We observed significantly elevated RRs with increasing duration of estrogen-only use across all strata of other ovarian cancer risk factors, including women with hysterectomy. The RR for estrogen-progestin use after prior estrogen-only use was 1.5 (95% CI, 0.91-2.4), but the RR for estrogen-progestin–only use was 1.1 (95% CI, 0.64-1.7). The RRs for less than 2 years and 2 or more years of estrogen-progestin–only use were 1.6 (95% CI, 0.78-3.3) and 0.80 (95% CI, 0.35-1.8), respectively, and there was no evidence of a duration response (P value for trend = .30).ConclusionWomen who used estrogen-only replacement therapy, particularly for 10 or more years, were at significantly increased risk of ovarian cancer in this study. Women who used short-term estrogen-progestin–only replacement therapy were not at increased risk, but risk associated with short-term and longer-term estrogen-progestin replacement therapy warrants further investigation.
Gastric Cancer in Japan — Honing Treatment, Seeking Causes
Authors: David Forman, Paola Pisani
Journal: New England Journal of Medicine (2008)

In this issue of the Journal, Sasako and colleagues (pages 453–462) present results from a randomized trial of surgery for gastric cancer conducted in 24 specialized hospitals in Japan. The 523 enrolled patients all had a diagnosis of curable gastric cancer and were randomly assigned to receive either Japan's standard surgical treatment — gastrectomy plus extensive removal of regional lymph nodes — or the same procedure plus para-aortic nodal dissection. There were no significant differences between the two groups in either overall 5-year survival (around 70% in both groups) or recurrence-free survival (around 63% in both groups). Given these results, . . .
Uptake of lndium-111-labeled Leukocytes in a Cutaneo-Cecal-Vaginal Fistula
Authors: HANI ABDEL-NABI, GEORGE H. HINKLE, HANS RICHTER, JOHN O. OLSEN
Journal: Clinical Nuclear Medicine (1984)

A cutaneo-cecal-vaginal fistula is demonstrated with ln-111 labeled WBCs in an 81-year-old patient. A barium follow-through and abdominal CT studies confirmed the findings of the WBC scan.
GALL STONES ASSOCIATED WITH ANOMALY OR INJURY OF BILE DUCTS
Authors: E. R. Flint
Journal: BMJ (1924)

THE first anid seconid of these three cases are very good examl)les of ttwo anomalies of the bile ducts, which I ,described recenitly in an Arris and Gale lecture (British Journ.1'al of Surgery, April, 1923).The third is one more instance of injury to the common duct.CASE I.A married woman, aged 32, spare, and of rather a delicate type, )iad had indigestion on and off for several years.The indigestion ras of the flatulent type with a good deal of discomfort soon after 'food, especially after certain kinds of food, such as fats and pastry.Considerable relief was obtained by belching.She had been liable to attacks of headache and what she called biliousness with vomiting.Bowels costive.Three weeks before admission she was suddenly seized with very severe pain across the upper abdomen gnd going through to the right shoulder-blade, requiring morphine.She was found to have a tender, distended gall bladder about the size of a smanl pear.There was no jaundice, and never had been any.Operation March 22nid, 1923.-Anincision was made through the upper ight reetus sheath and the muscle displaced outwards.A tightly distended gall bladder was found with a stone, as large as a hazel-nut, wedged into the com- mencement of the cystic duct.
Breast Cancer Screening: Benefits and Harms
Authors: Jill Jin
Journal: JAMA (2014)

Kevin C. Oeffinger, MD; Elizabeth T. H. Fontham, MPH, DrPH; Ruth Etzioni, PhD; Abbe Herzig, PhD; James S. Michaelson, PhD; Ya-Chen Tina Shih, PhD; Louise C. Walter, MD; Timothy R. Church, PhD; Christopher R. Flowers, MD, MS; Samuel J. LaMonte, MD; Andrew M. D. Wolf, MD; Carol DeSantis, MPH; Joannie Lortet-Tieulent, MSc; Kimberly Andrews; Deana Manassaram-Baptiste, PhD; Debbie Saslow, PhD; Robert A. Smith, PhD; Otis W. Brawley, MD; Richard Wender, MD
Persistent Treatment Effect Achieved At One Year After Four Doses Of Der p Derived Synthetic Peptide Immuno-Regulatory Epitopes In An Exposure Chamber Model Of House Dust Mite Allergy
Authors: Rod Hafner, Peter Couroux, Kristen Armstrong, AnneMarie Salapatek, Deepen Patel, Mark Larche
Journal: Journal of Allergy and Clinical Immunology (2014)
Chromosome 14 linkage analysis and mutation study of 2 serpin genes in allergic asthmatic families
Authors: Giovanni Malerba, Cristina Patuzzo, Elisabetta Trabetti, Maria C. Lauciello, Roberta Galavotti, Lydia Pescollderungg, Michael B. Whalen, Giovanna Zanoni, Laura C. Martinati, Attilio L. Boner, Pier Franco Pignatti
Journal: Journal of Allergy and Clinical Immunology (2001)
Elucidation of and therapeutic implications for adrenergic receptor concentration in the infundibular septum of cyanotic and acyanotic patients with right ventricular outflow tract obstruction
Authors: Lynn McGrath, Chao Chen, Debra Graf, Bridget Bailey, Seethapathy Muralidharan, John Bianchi, James Levett
Journal: Journal of the American College of Cardiology (1991)
Gene Expression Profiles Differentiating Between Breast Cancers Clinically Responsive or Resistant to Letrozole
Authors: William R. Miller, Alexey Larionov, Lorna Renshaw, Thomas J. Anderson, John R. Walker, Andreas Krause, Tobias Sing, Dean B. Evans, J. Michael Dixon
Journal: Journal of Clinical Oncology (2009)

Endocrine agents, such as letrozole, are established in the treatment of hormone-dependent breast cancer. However, response rates are only 50% to 70% in the neoadjuvant setting and lower in advanced disease. Thus there is a need to identify novel markers predicting for response and to understand molecular mechanisms of resistance.Sequential tumor biopsies were taken before and after 10 to 14 days of neoadjuvant treatment with letrozole in patients with estrogen receptor-rich breast cancer. Expression profiles on high-density microarray chips were then related to clinical responses as assessed from tumor volume measurements after 3 months of treatment.Of 52 patients, 37 (71%) were classified as having a clinical response to letrozole and 15 being clinically resistant. Bioinformatic analysis identified 205 covariables (69 baseline expression, 45 day 14 expression, and 91 change in expression with treatment) which differentiated between clinical responders and nonresponders. Hierarchical clustering using the variables separated responders and nonresponders into two distinct groups. Ontological assessment indicated that discriminating genes were enriched toward cellular biosynthetic processes. In particular, functional gene assessment showed ribosomal protein probes to have higher baseline expression in tumors responsive to letrozole and increased expression with treatment in nonresponding cases.To our knowledge, this is the first study to describe genetic covariables and molecular processes discriminating between tumors clinically responsive and resistant to an aromatase inhibitor. The understanding of such molecular phenotypes will be important in optimizing the clinical use of aromatase inhibitors, both in terms of identifying responsive breast cancers and developing new agents to target resistance pathways.